Key facts
- Iksuda Therapeutics’s last known valuation is $68.5M (Jun 2025).
- It has raised $77.2M; the latest was Later Stage VC ($18.2M) in Jun 2025.
- Notable investors include Innovate UK, Mirae Asset Capital, Premier Partners, Celltrion (Pharmaceuticals), IP — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Iksuda Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Iksuda Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iksuda Therapeutics
Developer of biological therapeutics designed to target difficult-to-treat cancers, including those resistant or refractory to current therapies. The company's therapeutics are antibody-drug conjugates that help in the treatment of cancer as well as tumor and tumor subtypes through careful selection of the right combinations of payload, linker, and conjugation chemistry, enabling patients to receive treatment for cancer.
- Sector
- Healthcare
- HQ
- Newcastle upon Tyne, United Kingdom
- Founded
- 2007
- Employees
- 43
- Website
- iksuda.com/
- Ownership
- Privately Held (backing)
Iksuda Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iksuda Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iksuda Therapeutics in its N-PORT filings yet. We sweep new filings monthly.